In the release issued under the same headline on May 10, 2018 by Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN ), please note that in the Consolidated Balance Sheets table, Cash and cash equivalents row, under March 31, 2018, the figure should read $16,199,481 rather than $6,199,481 as previously stated. The corrected release follows.
Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
- Patient screening and enrollment are underway in Phase 3 inoperable GBM brain cancer trial
- Key U.S. Patent Issued
- Clinical trial preparations are ongoing for Phase 2 trial with TSC in stroke
CHARLOTTESVILLE, Va., May 29, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN ) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients using the novel small molecule trans sodium crocetinate (TSC) in conjunction with standard radiation and chemotherapy, reports financial results for the three months ended March 31, 2018 and provides a business update.
“During the first quarter patients continued to be screened and enrolled into our lead clinical program, the IN vestigation of T SC A gainst C ancerous T umors (INTACT) trial for the treatment of inoperable glioblastoma multiforme, or GBM,” said David Kalergis, Chairman and Chief Executive Officer of Diffusion Pharmaceuticals. “In January the first patients were dosed in this 236-patient Phase 3 study. The protocol calls for half of patients to be enrolled in the treatment arm, which is standard of care radiation and chemotherapy, plus TSC, and half to be enrolled in the control arm, which is standard of care alone. The design of INTACT is based on an almost four-fold increase in overall survival at two years demonstrated in inoperable GBM patients in the preceding Phase 2 study. We are hopeful that similar survival will be demonstrated in our pivotal Phase 3 study and that TSC will provide an effective treatment for these patients, for whom current options are limited.”
The Company continues to prepare for a Phase 2, randomized, double-blind, placebo-controlled trial with TSC in acute stroke. The contemplated study, based on an abstract that was presented in January at the International Stroke Conference, calls for the administration of TSC by specially-trained Emergency Medical Technicians to ambulance-transported patients within two hours of the onset of a suspected acute stroke. The in-ambulance administration could potentially overcome the current severe timing delay in administering therapy to stroke patients. The trial, which has been named the P re- H ospital A mbulance S troke T rial - TSC (PHAST-T), is expected to commence in late 2018, subject to funding.
Diffusion is pleased to announce the granting of U.S. patent number 9,950,067, which expands the Company’s coverage of the use of TSC and related compounds in cancer therapy. The claims of the new U.S. patent relate to the treatment of a number of cancer types such as brain cancer (including glioblastoma) and pancreatic cancer, using TSC in conjunction with radiation therapy and chemotherapy. “This new U.S. patent further strengthens our IP portfolio in cancer treatment and is relevant to our technology in the Phase 3 study,” stated General Counsel and IP Counsel Thomas Byrne.
“Intellectual property is an important component of our growth strategy, and we are pleased this patent has issued,” Mr. Kalergis added. “We are expecting additional patent allowances in the near future that will further augment our IP.”
Financial Results for the Three Months Ended March 31, 2018
We had cash and cash equivalents of $16.2 million as of March 31, 2018. We believe that our cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements through June 2019.
We recognized $1.8 million in research and development expenses during the three months ended March 31, 2018, compared with $1.0 million during the three months ended March 31, 2017. The increase was mainly attributable to a $1.1 million increase in expense related to our Phase 3 GBM trial, offset by a $0.3 million decrease in manufacturing costs.
General and administrative expenses for the three months ended March 31, 2018 were $1.5 million compared with $1.6 million for the three months ended March 31, 2017. Salaries and wages increased by $0.2 million due to the increase in headcount, which was offset by a decrease in professional fees of approximately $0.3 million.
In connection with the private placement of our Series A preferred stock and common stock warrants in March of 2017, we determined the warrants to be classified as liabilities and subject to remeasurement at each reporting period. As a result, we recognized $10.2 million in excess fair value of the common stock warrants over the gross proceeds from our private placement. We also recognized $2.9 million in placement agent commission and other offering costs. In total, for the three months ended March 31, 2017, we recorded a $12.9 million expense for the change in fair value of our common stock warrant liabilities, which was primarily attributable to the increase in the market price for our Common Stock. There were no such charges in 2018 as the warrants were reclassified into equity in November of 2017.
About Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on improving patient outcomes in unmet medical needs using its novel small molecule trans sodium crocetinate (TSC). Diffusion is developing TSC for use in conditions where hypoxia (oxygen deprivation) is known to diminish the effectiveness of standard of care (SOC) treatments. In oncology, TSC targets the cancer's hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of SOC treatments without the apparent occurrence of any serious side effects. In non-oncology indications, therapeutic benefit would be achieved directly through re-oxygenation of the tissue threatened with cell death from hypoxia.
The IN vestigation of T SC A gainst C ancerous T umors (INTACT) Phase 3 randomized, controlled registration trial with TSC and SOC chemotherapy and radiation, compared with SOC alone in 236 patients who have been newly diagnosed with inoperable glioblastoma multiforme (GBM) brain cancer, is underway. In this study, TSC with concomitant temozolomide is being assigned to the first 8 subjects enrolled, and these patients will undergo radiation therapy plus temozolomide and TSC treatment through the normal six-week RT treatment period. During the subsequent temozolomide treatment period these subjects will be assigned TSC at ascending doses and studied in parallel for 2 full 28-day cycles. The Data Safety Monitoring Board will examine the resultant data and based on their observations may recommend the continued use of the starting TSC dose or another dose for those patients remaining to be randomized into the study.
A Phase 2 TSC clinical trial was completed in the second quarter of 2015 and evaluated 59 patients with newly diagnosed GBM. This open-label, historically controlled study demonstrated a favorable safety and efficacy profile for TSC combined with SOC, including a 37% improvement in overall survival compared with the control group at two years. A particularly strong efficacy signal was seen in the subset of inoperable patients where survival of TSC-treated patients at two years was nearly four-fold higher compared with the controls.
Due to its novel mechanism of action, TSC has safely re-oxygenated a range of tumor types in preclinical and clinical studies. Diffusion believes the therapeutic potential of TSC is not limited to specific tumors, thereby making it potentially useful to improve SOC treatments of other life-threatening cancers. Additional studies under consideration include Phase 2 trials in pancreatic cancer and brain metastases, with study initiation subject to receipt of additional funding or collaborative partnering. The Company also believes that TSC has potential application in other indications involving hypoxia including stroke, where the Company recently announced its P re- H ospital A mbulance S troke T rial - TSC (PHAST-T) study to be conducted in co-operation with the University of California Los Angeles (UCLA) and the University of Virginia (UVA) to test TSC in stroke patients in an in-ambulance clinical trial setting.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products, the potential of the company's technology and product candidates, the anticipated timing of future clinical trials, and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," "plans," "possibility," "potential," "future," "expects," "anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include: general business and economic conditions; the company's need for and ability to obtain additional financing; and the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and the various risk factors (many of which are beyond Diffusion’s control) as described under the heading “Risk Factors” in Diffusion’s filings with the United States Securities and Exchange Commission. All forward-looking statements in this news release speak only as of the date of this news release and are based on management's current beliefs and expectations. Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contacts: David Kalergis, CEO Diffusion Pharmaceuticals Inc. (434) 220-0718 dkalergis@diffusionpharma.com or LHA Investor Relations Kim Sutton Golodetz (212) 838-3777 kgolodetz@lhai.com
-Tables to Follow-
| Difusion Pharmaceuticals Inc. | ||||||
| Consolidated Balance Sheets | ||||||
| March 31, 2018 | December 31, 2017 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 16,199,481 | $ | 8,896,468 | ||
| Prepaid expenses, deposits and other current assets | 890,891 | 769,946 | ||||
| Total current assets | 17,090,372 | 9,666,414 | ||||
| Property and equipment, net | 432,634 | 460,652 | ||||
| Intangible asset | 8,639,000 | 8,639,000 | ||||
| Goodwill | 6,929,258 | 6,929,258 | ||||
| Other assets | 275,714 | 450,491 | ||||
| Total assets | $ | 33,366,978 | $ | 26,145,815 | ||
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity | ||||||
| Current liabilities: | ||||||
| Current portion of convertible debt | $ | 550,000 | $ | 550,000 | ||
| Accounts payable | 419,103 | 511,956 | ||||
| Accrued expenses and other current liabilities | 453,713 | 1,628,851 | ||||
| Total current liabilities | 1,422,816 | 2,690,807 | ||||
| Deferred income taxes | 2,223,678 | 2,223,678 | ||||
| Other liabilities | — | 1,386 | ||||
| Total liabilities | 3,646,494 | 4,915,871 | ||||
| Commitments and Contingencies | ||||||
| Convertible preferred stock, $0.001 par value: | ||||||
| Series A - 13,750,000 shares authorized at both March 31, 2018 and December 31, 2017. No shares and 12,376,329 shares issued at March 31, 2018 and December 31, 2017, respectively. No shares and 8,306,278 outstanding at March 31, 2018 and December 31, 2017, respectively. | — | — | ||||
| Total convertible preferred stock | — | — | ||||
| Stockholders’ Equity: | ||||||
| Common stock, $0.001 par value: | ||||||
| 1,000,000,000 shares authorized; 50,526,547 and 14,519,629 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively. | 50,526 | 14,520 | ||||
| Additional paid-in capital | 94,538,808 | 82,770,313 | ||||
| Accumulated deficit | (64,868,850 | ) | (61,554,889 | ) | ||
| Total stockholders' equity | 29,720,484 | 21,229,944 | ||||
| Total liabilities, convertible preferred stock and stockholders' equity | $ | 33,366,978 | $ | 26,145,815 | ||
| Diffusion Pharmaceuticals Inc. | |||||||
| Consolidated Statements of Operations | |||||||
| Three Months Ended March 31, | |||||||
| 2018 | 2017 | ||||||
| Operating expenses: | |||||||
| Research and development | $ | 1,825,568 | $ | 1,007,571 | |||
| General and administrative | 1,497,839 | 1,553,139 | |||||
| Depreciation | 28,018 | 6,603 | |||||
| Loss from operations | 3,351,425 | 2,567,313 | |||||
| Other expense | |||||||
| Interest (income) expense, net | (37,464 | ) | 55,719 | ||||
| Change in fair value of warrant liabilities | — | 12,919,674 | |||||
| Warrant related expenses | — | 10,225,846 | |||||
| Other financing expenses | — | 2,870,226 | |||||
| Net loss | $ | (3,313,961 | ) | $ | (28,638,778 | ) | |
| Accretion of Series A cumulative preferred dividends | (85,993 | ) | (58,845 | ) | |||
| Deemed dividend related to the make-whole provision for the conversion of Series A preferred stock into common | (8,167,895 | ) | — | ||||
| Net loss attributable to common stockholders | $ | (11,567,849 | ) | $ | (28,697,623 | ) | |
| Per share information: | |||||||
| Net loss per share of common stock, basic and diluted | $ | (0.27 | ) | $ | (2.78 | ) | |
| Weighted average shares outstanding, basic and diluted | 42,122,395 | 10,337,726 | |||||
